Get notified when SYRE files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStanding Risk Factors
- Going Concern (unchanged) — Going-concern risk remains despite cash more than doubling to $1.15B, as the company still needs to raise additional capital to fund operations.
- Material Weakness (unchanged) — Previously disclosed material weakness in internal control over financial reporting and related restatements are still described, with no indication of remediation completion.
Spyre posts positive SKYLINE data, raises; net loss narrows 1.4% to -$36.2M
Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 5, 2025 · ~1 min read
Key Changes
-
high
SKYLINE Part A topline data for SPY001 and SPY002 met primary endpoints with statistically significant RHI reductions (9.2 and 10.7 points) and clinically meaningful remission rates (40% and 33%).
MD&A: SKYLINE Phase 2 verify on EDGAR → -
high
cash and marketable securities more than doubled to $1.1B.
MD&A: Capital raise verify on EDGAR → -
high
R&D expenses jumped 63% YoY to $65.5M, driven by manufacturing, clinical trial, and compensation costs as pipeline advanced.
MD&A: R&D expenses verify on EDGAR →
2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (SAIC 10-Q) is open in full — no account needed.
Partner
Trade SYRE commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify